Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
- PMID: 20052966
- PMCID: PMC2964016
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy
Erratum in
- Cancer Immun. 2010 Feb 24;10:5. Ritter, Erika [added]
Abstract
Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.
Figures
Similar articles
-
Profile of ipilimumab and its role in the treatment of metastatic melanoma.Drug Des Devel Ther. 2011;5:489-95. doi: 10.2147/DDDT.S10945. Epub 2011 Dec 16. Drug Des Devel Ther. 2011. PMID: 22267918 Free PMC article. Review.
-
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.Cancer Immunol Immunother. 2009 Aug;58(8):1297-306. doi: 10.1007/s00262-008-0642-y. Epub 2009 Jan 13. Cancer Immunol Immunother. 2009. PMID: 19139884 Free PMC article.
-
Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi: 10.1056/NEJMoa1406498. Epub 2014 Nov 19. N Engl J Med. 2014. PMID: 25409260 Free PMC article.
-
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7. Clin Cancer Res. 2011. PMID: 21900389 Free PMC article. Review.
-
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Pharmacol Res. 2012. PMID: 21930211 Review.
Cited by
-
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.Int J Cancer. 2012 Jul 15;131(2):387-95. doi: 10.1002/ijc.26471. Epub 2011 Nov 9. Int J Cancer. 2012. PMID: 21964766 Free PMC article.
-
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.Ann Surg Oncol. 2013 Sep;20(9):3106-11. doi: 10.1245/s10434-013-2999-1. Epub 2013 May 17. Ann Surg Oncol. 2013. PMID: 23681603 Free PMC article.
-
Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review.J Neurol. 2025 Mar 5;272(3):249. doi: 10.1007/s00415-025-12992-7. J Neurol. 2025. PMID: 40042691
-
Biomarkers on melanoma patient T cells associated with ipilimumab treatment.J Transl Med. 2012 Jul 12;10:146. doi: 10.1186/1479-5876-10-146. J Transl Med. 2012. PMID: 22788688 Free PMC article.
-
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16723-8. doi: 10.1073/pnas.1110814108. Epub 2011 Sep 20. Proc Natl Acad Sci U S A. 2011. PMID: 21933959 Free PMC article.
References
-
- Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431–440. - PubMed
-
- Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162:5813–5820. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical